Proactive Investors - Run By Investors For Investors

Midatech revenue could jump by tenfold this year, says CEO Jim Phillips

Midatech Pharma (LON:MTPH) (NASDAQ:MTP) boss Jim Phillips says the firm could see as much as a "tenfold increase" in revenue this year.

His comments came after the company upgraded forecasts and said that its paediatric brain tumour treatment was chosen for a programme by the Bristol Royal Infirmary.

Midatech, which specialises in nano-technology by using tiny particles of pure gold to treat cancer and diabetes, acquired DARA Biosciences and Zuplenz last year.

The deals supplied the group's US commercial arm with four marketed oncology products.

Meet Sayona Mining Ltd, Lithium Power International Ltd, Elementos, Tyranna Resources and Argent Minerals Ltd at our event, Melbourne, 25 July 2017. Register here »
Why Invest In Midatech Pharma Plc? Read More Here

Register here to be notified of future Midatech Pharma Plc articles
View full MTPH profile View Profile

Midatech Pharma Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use